[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account

Courtney D. DiNardo, MD

Specialities: Acute Myeloid Leukemia

Spoken languages: English

Clinical Expertise

  • Acute Myeloid Leukemia

About

Dr. DiNardo's research focus is on analysis of isocitrate dehydrogenase (IDH) mutations, serum 2-hydroxyglutarate (2HG) levels, and patient outcomes in AML. Dr. DiNardo is the primary investigator of multiple novel IDH1 or IDH2-targeted therapeutic agents currently in clinical trials. Dr. DiNardo is also involved in the clinical development of the BCL2-inhibitor venetoclax (ABT-199) for myeloid malignancies. She is leading the study of venetoclax in combination with hypomethylating agent therapy for the treatment of newly diagnosed elderly AML patients.

Location

MD Anderson Cancer Center: 1515 Holcombe Blvd, Houston, TX 77030, USA

newsletter icon

Get the latest thought leadership on your Leukemia delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.